ACAD
29.24
+0.56
+1.95%
AEMD
2.13
-0.2
-8.58%
APRI
1.16
+0.07
+6.42%
ARNA
14.88
-1.31
-8.09%
ATEC
1.88
+0.02
+1.08%
CNAT
5.1
+0.14
+2.82%
CRXM
0.175
+0.00
+0.1719%
CYTX
1.04
0.00
0.00%
DXCM
77.33
-1.35
-1.72%
GNMK
12.75
+0.1
+0.79%
HALO
14.89
+0.06
+0.40%
ILMN
185.28
+2.29
+1.25%
INNV
0.12
+0.01
+9.55%
INO
8.2
+0.12
+1.49%
ISCO
1.15
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
123.87
+0.74
+0.60%
LPTN
2.93
-0.08
-2.66%
MBVX
1.538
+0.068
+4.5918%
MEIP
2.3
+0.14
+6.48%
MNOV
5.54
-0.02
-0.36%
MRTX
3.8
-0.25
-6.17%
MSTX
0.131
-0.007
-5.278%
NBIX
47.35
+0.23
+0.49%
NUVA
76.78
-0.13
-0.17%
ONCS
1.07
-0.07
-6.14%
ONVO
2.76
+0.05
+1.85%
OREX
3.12
+0.03
+0.97%
OTIC
18.75
+1
+5.63%
QDEL
27.38
+0.89
+3.36%
RCPT
231.96
0.00
0.00%
RGLS
0.915
-0.075
-7.576%
RMD
78.44
+0.81
+1.04%
SCIE
0
0.00
0.00%
SPHS
2.06
0.00
0.00%
SRNE
1.85
-0.1
-5.13%
TROV
1.14
-0.16
-12.31%
VICL
2.45
-0.03
-1.21%
VOLC
18
0.00
0.00%
ZGNX
15
0.00
0.00%
ACAD
29.24
+0.56
+1.95%
AEMD
2.13
-0.2
-8.58%
APRI
1.16
+0.07
+6.42%
ARNA
14.88
-1.31
-8.09%
ATEC
1.88
+0.02
+1.08%
CNAT
5.1
+0.14
+2.82%
CRXM
0.175
+0.00
+0.1719%
CYTX
1.04
0.00
0.00%
DXCM
77.33
-1.35
-1.72%
GNMK
12.75
+0.1
+0.79%
HALO
14.89
+0.06
+0.40%
ILMN
185.28
+2.29
+1.25%
INNV
0.12
+0.01
+9.55%
INO
8.2
+0.12
+1.49%
ISCO
1.15
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
123.87
+0.74
+0.60%
LPTN
2.93
-0.08
-2.66%
MBVX
1.538
+0.068
+4.5918%
MEIP
2.3
+0.14
+6.48%
MNOV
5.54
-0.02
-0.36%
MRTX
3.8
-0.25
-6.17%
MSTX
0.131
-0.007
-5.278%
NBIX
47.35
+0.23
+0.49%
NUVA
76.78
-0.13
-0.17%
ONCS
1.07
-0.07
-6.14%
ONVO
2.76
+0.05
+1.85%
OREX
3.12
+0.03
+0.97%
OTIC
18.75
+1
+5.63%
QDEL
27.38
+0.89
+3.36%
RCPT
231.96
0.00
0.00%
RGLS
0.915
-0.075
-7.576%
RMD
78.44
+0.81
+1.04%
SCIE
0
0.00
0.00%
SPHS
2.06
0.00
0.00%
SRNE
1.85
-0.1
-5.13%
TROV
1.14
-0.16
-12.31%
VICL
2.45
-0.03
-1.21%
VOLC
18
0.00
0.00%
ZGNX
15
0.00
0.00%
Home » Events, SDBN Events

SDBN Networking Event Featuring Fate Therapeutics & Stemgent

Submitted by on July 1, 2009 – 11:41 am

The San Diego Biotechnology Network’s July 21st event will feature Fate Therapeutics and Stemgent, two companies engaged in exciting, interdisciplinary biotechnology research in San Diego that holds direct promise for making a difference in our quality of life. Ken Batchelor, Ph.D., CSO, Fate Therapeutics, and Stephen Chang, Ph.D., CSO, Stemgent will present a short talk which will be followed by networking:

CATALYST: The Industrialization of Advanced iPSC Technology for Drug Discovery & Development

For more information visit http://sdbn.org/july

Be Sociable, Share!